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Abstract
Smoking is a leading global cause of disease and mortality1. We performed a genomewide meta-
analytic association study of smoking-related behavioral traits in a total sample of 41,150
individuals drawn from 20 disease, population, and control cohorts. Our analysis confirmed an
effect on smoking quantity (SQ) at a locus on 15q25 (P=9.45e-19) that includes three genes
encoding neuronal nicotinic acetylcholine receptor subunits (CHRNA5, CHRNA3, CHRNB4).
We used data from the 1000 Genomes project to investigate the region using imputation, which
allowed analysis of virtually all common variants in the region and offered a five-fold increase in
coverage over the HapMap. This increased the spectrum of potentially causal single nucleotide
polymorphisms (SNPs), which included a novel SNP that showed the highest significance,
rs55853698, located within the promoter region of CHRNA5. Conditional analysis also identified
a secondary locus (rs6495308) in CHRNA3.
Smoking behavior and Nicotine Dependence (ND) are multifactorial traits with substantial
genetic influences2. There is an urgent need to better understand the molecular neurobiology
of ND, in order to design targeted, more effective therapies3. Recently, genome-wide
association scans (GWAS) have established one locus in ND and Smoking Quantity (SQ),
which implicates a cluster of three genes encoding neuronal nicotinic acetylcholine receptor
subunits, CHRNA5, CHRNA3, and CHRNB4, on chromosome 15q254–8. The locus is also
associated with lung cancer7,9,10, peripheral arterial disease7, and chronic obstructive
pulmonary disease and lung function11.
We initially performed a GWAS meta-analytic study of smoking-related traits in a total
sample of 41,150 individuals of white European descent, sourced from multiple disease,
population and control cohorts (Table 1, Supplementary Table 1, Online Methods). As the
cohorts were genotyped on a variety of different genome-wide SNP arrays (Table 1,
Supplementary Table 1), we first imputed genotypes for all datasets12, for all SNPs in the
HapMap version release 2213.
The main focus of our analysis was on SQ within current or past smokers, as a semi-
quantitative trait based on the self-reported variable of Cigarettes-per-Day (CPD)7. We
performed association analysis separately within each cohort under an additive model, using
covariate effects for age and sex, disease case/control status where applicable, and other
cohort-specific covariates (Supplementary Table 1). The meta-analysis was then carried out
by combining study-specific β- estimates using a fixed effects model14. In total, 15,574
subjects reported CPD values >0 and were used for meta-analysis of SQ (Table 1,
Supplementary Table 1). We followed up our most promising association findings by
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comparing them with results from two concurrent GWAS meta-analyses of smoking; the
ENGAGE study of 46,481 subjects15, and the TAG study of 74,035 subjects16. We also
made our meta-analysis results available to the authors of those studies to check their top
findings for replication.
Our meta-analysis of SQ identified the CHRNA5/CHRNA3 locus on 15q25 as the single
outstandingly significant locus in the genome (Figure 1, Table 2, Supplementary Table 2),
with a minimum P=9.45e-19 for rs1051730, which has been a SNP commonly reported4–8,
and very low P values for many other SNPs in the region (Supplementary Figure 1,
Supplementary Table 2). All cohorts in the analysis contributed at least somewhat to the
15q25 association (Supplementary Figure 1). Each copy of the ‘high-smoking’ A allele
(34% frequency) had a quantitative effect size on SQ of 0.079 (95% CI 0.070–0.088) which
is inline with previous estimates7. Joint analysis of our total dataset together with TAG and
ENGAGE, for rs1051730, yielded P=1.71E-66 (Table 2).
Multiple variants at the 15q25 locus have been suggested to underlie its effect, including a
non-synonymous SNP in CHRNA5, together with variants that affect mRNA expression
levels17–19. We decided to use our very large sample, in combination with data from the
1000 Genomes Project (see URL below), to perform fine mapping and modeling of the
15q25 locus in relation to SQ. We reasoned that, with the near complete information on
common variants derived from 1000 Genomes, it might be possible to pinpoint a variant, or
combination of variants, that can explain all the signal of association at 15q25. We used data
from 108 estimated CEU haplotypes from the April 2009 release of the 1000 Genomes Pilot
1 data. This contained 2189 SNPs in our region of interest (See Online Methods),
approximately a five-fold increase in coverage compared to 437 SNPs in release 22 of the
HapMap. By imputing genotypes for all SNPs across this locus from 1000 Genomes, and
repeating the meta-analysis, we found that the most significant association was with a novel
and previously untested SNP, not in the HapMap, located within the 5' untranslated region
(UTR) of CHRNA5, which makes it a candidate for affecting mRNA transcription
(rs55853698, P = 1.31E-16; Figure 2). The p-value for the commonly reported SNP
rs1051730 in this analysis was similar but a little higher, P=1.47E-15. (P values for our 1000
Genomes analysis are generally higher than our HapMap-based analysis because not all
cohorts were included in the 1000 Genomes imputation - see Online Methods.) SNP
rs55853698 is a G/T substitution where the G allele has a frequency ranging from 0.313 to
0.378 across the various cohorts.
To investigate whether the association at 15q25 can be explained completely by rs55853698,
we carried out tests of association for all SNPs spanning the CHRNA5/CHRNA3 locus
conditional upon this SNP (Figure 2). Residual association was still detected at many SNPs
in the region, with the most significant signal occurring at rs6495308 (P= 3.96E-05), located
within an intron of CHRNA3 (Figure 2). In unconditioned analysis rs6495308 has a
marginal association in the meta-analysis of P=3.30E-10. Further conditioning on
rs6495308, after already conditioning on rs55853698, leaves no obvious signal of
association in the region (Supplementary Figure 2), suggesting that these two SNPs together
could be sufficient to explain this genetic effect.
Wang et al.18 suggested that a non-synonymous SNP rs16969968, in CHRNA5, is
functional for ND risk (and lung cancer risk), but also that variants that cause high
expression of CHRNA5 mRNA, tagged by SNP rs588765, increase the risk for ND
independently. The marginal p-values of rs16969968 and rs588765 in our meta-analysis
were P=1.64E-18 and P=1.74E-03. Conditional analysis on rs16969968 within our cohorts
still left residual association within the region (Supplementary Figure 2), with the most
significant signal again occurring at rs6495308 (P=1.54E-05). Conditioning on both
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rs16969968 and rs588765, i.e. the proposed combination of Wang et al.18, leaves no obvious
signal of association (Supplementary Figure 2). To further investigate which pair of SNPs
best explains the signal of association we used the Bayesian Information Criteria (BIC)
measure of model fit 20. For the model of Wang et al.18, i.e. conditioning on both
rs16969968 and rs588765, we obtained BIC = 22719.87, posterior probability 0.15. For the
model conditioning on the novel promoter SNP rs55853698, and rs6495308, we obtained
BIC = 22716.49, posterior probability 0.85, which indicates a better model fit.
Examination of the LD structure between the SNPs that we have considered shows that
rs1051730, rs16969968, and rs55853698 are all close tagging proxies of each other (all
pairwise R2 > 0.96). These variants tag, or cause, the principal risk for high SQ attributable
to the 15q25 locus, but the high LD makes it difficult to assign causality. The ‘residual
association’ SNPs rs588765 and rs6495308 are in low LD with each other (R2 = 0.21), and
are both only in modest LD with the principal SNPs (maximum R2 = 0.47). It is not
therefore clear that this locus can be completely understood in the way proposed by Wang et
al.18. While the non-synonymous SNP in CHRNA5, rs16969968, may be important, we
have identified a novel and potentially functional SNP in the 5' UTR of this gene that is a
close proxy to the non-synonymous SNP in terms of LD, but shows a slightly more
significant association in our meta-analysis. Then, while rs588765 can explain much of the
secondary or residual association at this locus, we find that a largely independent variant
within CHRNA3, rs6495308, is the best tagger of the residually associated variation, while
also contributing to a better fitting 2-SNP model, and having a much stronger marginal
significance in unconditioned analysis (P=3.30E-10 for rs6495308 compared to P=1.74E-03
for rs588765).
Our analysis has, for the first time, surveyed virtually all of the common variants in the
15q25 region, and provides one of the first examples of how data from the 1000 Genomes
Project can contribute new information to mapping and characterizing loci for complex
traits. We recommend that further analysis of this locus should not be limited in focus to
CHRNA5, nor particularly to the common, non-synonymous SNP rs16969968. It is
notoriously difficult to distinguish functional variation in the context of high LD across a
region21. There are numerous ways in which variants can be functional, including
expression regulatory changes that affect close or distant genes, epigenetic changes, splicing
effects, alterations to microRNA binding sites, or non-coding RNAs21. It is also conceivable
that association with common variants can arise through the effects of multiple rarer variants
that happen to be relatively restricted to specific haplotype backgrounds.
The second strongest association within the genome in our meta-analysis, for SQ, was at a
locus on 8p21 that received modest support from the TAG and ENGAGE studies
(Supplementary Table 2, Supplementary Figure 3; P=5.26E-07 for rs11782673). This locus
would not survive correcting for genome-wide multiple testing, although it is noteworthy
that the locus spans another neuronal nicotinic acetylcholine receptor subunit gene,
CHRNA2.
In addition to our analysis of SQ, we also tested genome-wide for allelic differences
between those who reported currently smoking, or smoking in the past, versus those who
said they had never been smokers (the EVER/NEVER phenotype; sample sizes in Table 1,
Supplementary Table 1). This was in order to identify genetic effects on the establishment of
a smoking habit. No locus achieved genome-wide significance, and none of the top 15 loci
showed evidence for replication (Supplementary Table 2, Supplementary Figure 4).
Likewise, no consistent results emerged when we tested for allelic differences between those
who reported currently smoking versus those who had smoked in the past but had stopped at
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the time of interview (Supplementary Table 2, Supplementary Figure 4). When age-
adjusted, this is a rough measure of smoking cessation.
Our study identified association at some loci which, while not reaching genomewide
significance in our own meta-analysis, supported findings from the concurrent TAG and
ENGAGE studies15,16. These include novel loci on chromosomes 8 and 19 for SQ, 11 for
EVER/NEVER, and 9 for Current/Non-Current15,16. These findings have provided further
novel insights into the biology of smoking behavior.
ONLINE METHODS
Study samples
Study collections and their basic characteristics are listed in Table 1 and Supplementary
Table 1. Subjects used in our analysis were adults of white European descent. Summary
descriptions of the collections are given below, together with primary citations that describe
the collections fully. Data were used in accordance with the ethical permissions and
consents relating to each collection.
GEMS22: The Genetic Epidemiology of Metabolic Syndrome (GEMS) study consists of
dyslipidaemic cases (age 20–65 years) matched with normolipidaemic controls by sex and
recruitment site, drawn from non-Mediterranean subjects of the Genetic Epidemiology of
Metabolic Syndrome study (Finland, Switzerland, Canada, Australia, USA).
CoLaus23: The Cohorte Lausannoise (CoLaus) is a single-center, cross-sectional population-
based study, including individuals aged 35 to 75 years randomly selected from the list of
residents of the city of Lausanne (Switzerland).
GSK COPD11: This collection includes cases with chronic obstructive pulmonary disease
diagnosed according to Global Initiative of Chronic Obstructive Lung Disease (GOLD)
criteria, and unaffected controls recruited from Bergen, Norway.
GSK UPD24: This collection includes cases with recurrent major depression according to
DSM-IV criteria and age- and gender-matched non-affected controls, recruited at the Max-
Planck Institute of Psychiatry in Munich, Germany; patients were also recruited at two
satellite recruiting hospitals (BKH Augsburg and Klinikum Ingolstadt) in the Munich area.
GSK Bipolar25: The Bipolar collection includes DSM-IV Bipolar cases and controls from
subjects recruited at 3 study sites: the Institute of Psychiatry (IOP) in London, U.K.; the
Centre for Addiction and Mental Health in Toronto, Canada; and the University of Dundee,
U.K.
GSK Lolipop26: The London Life Sciences Prospective Population (LOLIPOP) is a
population based study including Indian Asian and European white men and women
recruited from the lists of 58 General Practitioners in West London.
GSK Medstar27: The MedStar cohort includes cases with acute coronary syndrome or
chronic coronary artery disease from Washington DC, and unaffected controls.
PennCath27: The Penn-CATH cohort is a University of Pennsylvania Medical Center based
angiographic study, from which cases with coronary artery disease (CAD) and controls with
no evidence of CAD at the coronary angiography were derived.
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EPIC28: The EPIC-Obesity cohort is a case-control cohort for obesity drawn from the EPIC-
Norfolk cohort, which includes white European men and women aged 39–79 years recruited
in Norfolk, UK.
KORA29: The Co-operative Health Research in the Region of Augsburg (KORA) study is
an epidemiological survey of the general population living in the city of Augsburg, Southern
Germany, and two adjacent counties.
WTCCC HT30: The WTCCC-HT collection comprises severely hypertensive probands
ascertained from families with multiple affected members in the UK as part of the BRIGHT
study.
WTCCC CAD, WTCCC CD, WTCCC RA30: include patients with Coronary Artery
Disease, Chrohn’s disease and Rheumatoid Arthritis from the Wellcome Trust Case Control
Consortium Study.
POPGEN study31: The Population Genetic Cohort (POPGEN) is a cross sectional
epidemiological surveys of regional German populations from Schleswig-Holstein, northern
Germany.
SHIP Study32: The Study of Health in Pomerania (SHIP) is a longitudinal, population-based
survey from West Pomerania, Germany. Data from the baseline cohort were used for this
study.
VIS Study33: This study includes unselected Croatians, aged 18–93 years, recruited from the
villages of Vis and Komiza on the Dalmatian island of Vis.
ORCADES Study34: The Orkney Complex Disease Study is a family-based, cross-sectional
study that seeks to identify genetic factors influencing cardiovascular and other disease risk
in the population isolate of the Orkney Isles in northern Scotland.
KORCULA Study35: The KORCULA study includes healthy volunteers aged 18 and over
from the villages of Lumbarda, Žrnovo, and Račišće on the Island of Korcula, Croatia.
SardiNIA Study36: The SardiNIA is a population-based longitudinal cohort study that
includes male and female related individuals, aged 14 years and above, from a cluster of
four towns in the Ogliastra province of Sardinia, Italy.
Genotyping, quality control and imputation
Supplementary Table 1 lists the various genotype platforms used for each cohort, genotype
calling algorithms, SNP and sample quality control, and details of the imputation and
association analysis software used. The quality control measures from previous analyses of
each cohort were adopted for this study and are detailed in the table. We used NCBI Build
36 co-ordinates for SNP base-pair positions so that all the cohorts could be combined
seamlessly.
We imputed all SNPs reported in the CEU sample in HapMap Phase II using various
imputation algorithms12,37 (see the URL section for a link to the software ProbABEL).
Imputations were performed after excluding samples and SNPs that did not meet the study-
specific quality control criteria. Genotypes were imputed for SNPs not present in the
genome-wide arrays or for those where genotyping had failed to meet the QC criteria.
Only imputed SNPs with good imputation quality were included in the meta-analysis. This
was defined as proper_info≥0.5 (for studies analysed with IMPUTE/SNPTEST12) or rsq-
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hat≥0.5 (for studies analysed using MACH37) and Imp_info≥0.5 (for studies analysed using
ProbABEL).
Derivation of smoking phenotypes
We used the categorical SQ levels defined by Thorgeirsson et al.7. The SQ levels were 0 (1–
10 cigarettes per day), 1, (11–20), 2 (21–30) and 3 (31 or more). Each increment represents
an increase in SQ of 10 cigarettes per day. Most of the cohorts in our study have maximal
CPD recorded on each sample but a few have collected average CPD (Supplementary Table
1). We examined the distributions of CPD across cohorts and found no large differences
between those cohorts with average or maximal CPD. The mean and standard deviation of
the CPD measurements in each cohort are given in Supplementary Table 1. The Ever/Never
and Current/Non-current phenotypes used were those collected by the individual cohorts.
Not all cohorts had all three phenotypes collected. Precise details of the phenotypes
collected in each cohort are given in Supplementary Table 1. An assessment would typically
be questionnaire-based, following a structure such as:
Tick the option that best describes you:
- I smoke now
- I don’t smoke now. I have stopped for … years.
- I have never smoked
About how many cigarettes do you or did you smoke per day?
Put the number of years you have smoked.
Statistical Analysis and Meta-analysis
Each cohort was analyzed separately for each of the 3 phenotypes considered. The majority
of the analysis was carried out on the raw genotype data in Oxford but some cohorts
(SardiNIA, VIS, KORCULA, ORCADES, SHIP) carried out their own analysis and
submitted results for the meta-analysis. For the binary traits (Ever/Never, Current/Non-
Current) tests for additive genetic effects on the logodds scale were carried out using logistic
regression. For the categorical SQ phenotype, tests for additive genetic effects were carried
out on a linear scale using linear regression. The programs SNPTEST, probABEL and
MERLIN were used on the various cohorts to fit these models taking account of the
genotype uncertainty at imputed SNPs. All tests conditioned on Sex and Age and for some
cohorts other covariates of self-reported ancestry, country of origin or PCA-derived
covariates were included (a complete list is given in Supplementary Table 1). A Genomic
Control (GC) lambda estimate was calculated for each phenotype and each cohort
(Supplementary Table 3).
The meta-analysis was carried out by combining study-specific β-estimates using a fixed
effects model14 using the inverse of the variance of the study-specific β-estimates to weight
the contribution of each study. The variance of each cohort’s β-estimate was multiplied by
the GC lambda estimate to correct for observed inflation38. Specifically,
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where βi  and λi are the β-estimate, β-estimate variance and GC lambda estimate for
the ith cohort. This method is appropriate when the same phenotype and measurement scale
are used in each cohort and has the advantage that measures of effect size (eβ is an estimate
of the Odds Ratio of the risk allele) and its standard error can be calculated. We also
repeated the analysis of SQ by combining Z-scores from each cohort weighted by their
sample size38 and obtained almost identical results. All meta-analysis was carried out using
the SNPMETA program (see URL list). After performing each meta-analysis the overall
lambda estimate for each phenotype was: SQ 1.0145, Ever/Never 1.002, Current/Non-
Current 0.998. For each SNP we also calculated a p-value for the heterogeneity across the
studies38.
SNP selection for replication
In collaboration with two other groups carrying out similar meta-analysis of smoking related
traits (ENGAGE15 and TAG16) we agreed to an in-silico replication strategy in which for
each phenotype (SQ, EVER/NEVER, CURRENT/NON-CURRENT) each group would
select 15 regions of the genome showing evidence for association, and summary data (p-
values, β-estimate, β-estimate variances, sample sizes, GC-lambda estimates and sample
sizes) would be shared across groups to facilitate replication. We selected the top 15 regions
for each phenotype based on the p-values we obtained in our own meta-analysis. We
excluded regions in which only a small number of cohorts contributed to the study because
the information measure at the SNPs in the excluded cohorts were below our thresholds, or
where the heterogeneity between the studies was high. Each selected region consisted of
several SNPs showing evidence of association in our meta-analysis with p-values below
1e-5. For each of the three phenotypes the results from all the cohorts in all three concurrent
studies were combined together using the same GC-corrected inverse-variance meta-analysis
method described above. A full list of the selected regions and the summary information
from all 3 phenotypes is given in Supplementary Table 2.
1000 Genomes imputation analysis of the 15q22 associated region for SQ
We used 108 estimated CEU haplotypes from the April 2009 release of the 1000 Genomes
Pilot 1 data to carry out our fine-mapping experiments at the 15q25 locus (see the URL list
for a link to the data source). We used these haplotypes to carry out imputation in the
interval 76.4–77.0Mb on chr15 in 12 of the cohorts (GSK-Bipolar, GSK-Unipolar, GSK-
COPD, KORA, POPGEN, Lausanne, GSKLolipop, GSK-GEMS, Medstar, SHIP, WTCCC-
CAD and WTCCC-HT) using the program IMPUTE12. This release contains 2189 SNPs in
this interval compared to 437 SNPs in release 22 of the HapMap data. Meta-analysis of the
imputed data was then carried out in the same way as described above. An important
technical detail when carrying out imputation using the 1000 Genomes haplotype data is
how to align it with the genotype data from genome-wide studies. The program IMPUTE
aligns SNPs between the haplotype and genotype data based on base-pair position (and not
using SNP identifiers such as rs IDs) so as long as the same co-ordinate system is used for
both the haplotype and genotype data the alignment is automatic.
Conditional analysis and modeling
The analysis conditional upon SNPs was carried out using all of the centrally analyzed
cohorts (Bipolar, Unipolar, COPD, KORA, POPGEN, Lausanne, LOLIPOP, GEMS,
MEDSTAR, SHIP, WTCCC-CAD and WTCCC-HT). At the SNP being conditioned upon
we used expected genotype counts as this allowed us to combine data from cohorts which
had imputed the SNP and cohorts which had genotyed the SNP. These expected counts
where included into the baseline null model as an additional covariate along with the other
covariates such as Age, Sex and covariates coding for population structure. The same
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method was used when conditioning upon two SNPs. The model selection analysis of the
two pairs of SNPs in the 15q25 region was carried out using the expected genotype counts.
Analysis was carried out using the R statistical package.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Manhattan plot showing the significance of association of all SNPs in genome-wide SQ
meta-analysis. SNPs are plotted on the x-axis according to their positions on each
chromosome, against association with SQ on the y-axis (−log10 P-value). SNPs with p-
values less than 1.0E-05 are highlighted in green.
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Figure 2.
Chromosome 15q25 signal plots. Top: Signal plot based on 1000 Genomes imputation and
meta-analysis of SQ association. SNPs are plotted by their positions on the chromosome,
against association with SQ (−log10 p-value) on the left Y-axis. The five SNPs with the
lowest p-values from the HapMap imputation are highlighted in red. The five SNPs with the
lowest p-values from the 1000 Genomes imputation are highlighted in green (unless already
coloured red). The rs identities of highlighted SNPs are given in the box. Recombination
rates across the region are shown by the red line plotted against the right y-axis. Middle:
Chromosome 15q25 signal plot based on 1000 Genomes imputation and meta-analysis of
SQ association, conditional on the SNP rs55853698. The five SNPs with the lowest p-values
from the conditional analysis are highlighted in green. The five SNPs with the lowest p-
values from the unconditioned HapMap-imputation analysis are highlighted in red. Bottom:
Genes and the positions of exons (using data from the UCSC genome browser; URL is given
below).
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